Answers are grounded in this paper and cite their sources.
Experimental study demonstrates high-yield N-acetylneuraminic acid production in engineered Escherichia coli, indicating the utility of deep learning for resolving metabolic bottlenecks.
N-Acetylneuraminic acid (NeuAc) is a sialic acid valued in pharmaceuticals and infant nutrition, and microbial synthesis offers a scalable route once the pathway’s catalytic bottlenecks are relieved. We combine deep learning with metabolic engineering to build a high-titer NeuAc-producing E.coli strain. Modular pathway engineering reaches 1.25 g L−1 and pinpoints N-acetylglucosamine 2-epimerase (AGE) as the rate-limiting step. We develop DLCatalysis, a deep learning framework that predicts kcat Km−1 directly from protein sequence and substrate, and use it to mine AGEBf that lifts the titer to 6.84 g L−1. DLCatalysis-guided redesign of AGEBf and NeuBNm raises NeuAc to 9.27 g L⁻¹, and identifying and deleting exuT, a previously unannotated NeuAc transporter, blocks product reuptake. In 5-L fed-batch fermentation the optimized strain produces 85.5 g L−1, showing that AI-guided enzyme discovery can resolve the bottlenecks that have limited microbial NeuAc production. N-Acetylneuraminic acid (NeuAc) is a valuable pharmaceutical. Here the authors develop DLCatalysis, a deep learning framework that predicts kinetics from protein sequence and substrate, and use DLCatalysis to mine enzymes for NeuAc production in E. coli.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: